+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition of plasma fibrinolytic parameters in patients with heart failure



Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition of plasma fibrinolytic parameters in patients with heart failure



Circulation 99(23): 2983-2985, June 15



Background-Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibronolytic parameters. The aim of the present study was to determine whether acute ACE inhibition and angiotensin II type 1 (AT1) receptor antagonism have similar effects in patients with heart failure. Methods and Results-Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design. Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity were measured at baseline and 6 hours after the dose. Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1 (38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in PAI-1 (48%; P=0.01) activity. Changes in plasma fibrinolytic parameters were more marked during losartan treatment (P<0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (P<0.05). Conclusions-Acute AT1 antagonism in patients with heart failure is associated with a significant improvement in plasma fibrinolytic parameters that is greater than during ACE inhibition. These beneficial effects of AT1 antagonism and ACE inhibition would therefore appear to be mediated principally through suppression of angiotensin II.

(PDF emailed within 1 workday: $29.90)

Accession: 010544166

Download citation: RISBibTeXText

PMID: 10368114


Related references

Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure. Thrombosis and Haemostasis 86(6): 1585-1586, 2002

Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34(2): 285-290, 1999

Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation. Basic Research in Cardiology 94(2): 128-135, 1999

Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Cardiovascular Research 39(2): 413-422, 1998

Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 313(4): R410-R417, 2017

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. International Journal of Cardiology 77(2-3): 131-138, 2001

Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors. Journal of the Renin-Angiotensin-Aldosterone System 9(1): 22-26, 2008

Chronic combined angiotensin converting enzyme inhibition and angiotensin type-1 receptor blockade Unique effects in congestive heart failure. Circulation 94(8 SUPPL ): I429, 1996

Effects of angiotensin-converting enzyme inhibition and angiotensin II AT-1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. American Journal Of Cardiology. 80(suppl. 3a): 110a-117a, 1997

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. Journal of Clinical Investigation 99(8): 1926-1935, 1997

Effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on coronary endothelial vasomotion and fibrinolysis. Circulation 104(17 Supplement): II 285, October 23, 2001

Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59(6): 1195-1203, 2012

Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. Journal of the American College of Cardiology 41(8): 1373-1379, April 16, 2003

ETA receptor antagonism, angiotensin type 1 receptor antagonism, angiotensin-converting enzyme inhibition and combined treatments after experimental myocardial infarction in stroke-prone spontaneously hypertensive rats. European Heart Journal 24(Abstract Supplement): 170, August-September, 2003

Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Basic Research in Cardiology 94(2): 128-135, 1999